AGAP1

Across TCGA pan-cancer cohorts, AGAP1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGAP1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AGAP1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AGAP1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where AGAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.700	0.328	.011	29	view →
PDAC	OS	Median	IV	0.951	0.381	.006	11	view →
UCEC	DFS	Median	All	1.000	0.939	.028	8	view →
GBM	DFS	Quartile	All	0.952	0.741	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AGAP1–CCRCC (DFS)

Open the CCRCC breakdown →